Views & Analysis Case study: Ensuring safety by digitally linking prescriptio... Monitoring people who are on disease modifying drugs (DMDs) is paramount to providing safe, high-quality MS care.
Views & Analysis ‘Listen to your patients’: the best MS care honoured at QuDo... Best healthcare professionals working in multiple sclerosis (MS) honoured QuDoS awards.
News Gilead's twice-yearly PrEP drug is cleared by FDA Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
